Archives For Featured Datacard

Our Editor’s pick for Datacard of the week, used in weekly newsletter to users

#IceBucketChallenge

abbywellskd —  August 8, 2014 — 1 Comment

I think by now if you are living in or around Boston you have heard of the #IceBucketChallenge to #StrikeoutALS.  The Ice Bucket Challenge was created to raise awareness for support of ALS and more specifically Pete Frates.  Pete is a former Boston College baseball captain who is battling the disease. If you are nominated to complete the challenge, you must film yourself pouring a bucket of ice water on your head, after nominating others to complete the challenge within 24 hours.  By now you have probably seen Pro Athletes, friends, family, and even politicians completing this challenge.

While watching Pete Frates’ video on his site, I learned what rewriting the end of ALS meant to him.  “Rewriting the end of ALS means raising money to get better research for treatment and ultimately finding a cure.”  So if you head over to karmadata, we can dig into the research part of ALS.  You are able to see below that the number of Industry Sponsored ALS trials are declining.  As Pete said, the way to a cure is through research.  We need to raise the amount of research that is being done.

ALS TrialsIf you head over to Sponsor Finder and search for ALS Trials, you will see that there are only 8 companies actively conducting ALS clinical trials.

ALS

 

Lastly, this data card below shows government funding.  John Hopkins University being the top organization who grants money to ALS.

ALS_Grant Money

 

So what does all this mean?  This challenge is to create awareness for ALS and I believe it is working.  When I log in to facebook, it’s the first thing I see and it fills my news feed from top to bottom.  By creating awareness, we are able to become more knowledgable on ALS and more likely to donate to the cause, which will hopefully result in more research.  With all of the visualizations on funding and number of companies/trials, you can see that ALS may not be something people are too aware of.  The Challenge will definitely not cure anything right away, but it is a big step in the right direction!

A couple of us here at karmadata have already donated to ALS and completed the Ice Bucket Challenge, even our CEO Sean Power who completed it last night!  We urge you to visit petefrates.com and donate!  You can also check out the sweet Frate Train gear at petefrates.storenvy.com

 

Advertisements
Vaccine Trials Data Card
medicare-reimbursement-drg

Major joint replacements cost Medicare more than $6B in 2011

Yesterday there was quite a bit of buzz about the release of Medicare’s inpatient payments for the top 100 diagnosis related groups.  The Washington Post published some highlights on the data including a neat widget to visualize the data.  We decided to take our own shot at it.  This was a fun dataset for us since we were able to leverage a ton of work that we’ve already done.  We had already standardized entities for hospital, organization, DRG, and city from other CMS datasets.  I downloaded the data at 3 PM and had it up and running on karmadata by 5.  We added a couple of calculated measures for total amount paid by Medicare and discrepancy between amount charged and amount received, and started making datacards.

Here’s what folks are saying:

Orphan Drug Designations

Orphan drugs have been a hot topic of late.  We created this card which shows a steady increase in the number of companies receiving orphan drug designations from the FDA.

Image

This datacard caught our eye since we’ve seen recent news reports on the increased requests by foreign governments for user data to Google and Microsoft as reported by Forbes. Events such as Monday’s Boston bombings likely cause a spike in such activity (and for good reason).

Trend of Novartis Cancer Trials

Trend of Novartis Cancer Trials

This week’s featured datacard is from our friend (and thoughtful beta user) Moe Alsumidaie from Annex Clinical.  The datacard trends Novartis’ cancer (ICD-9 140-239) trials over time by trial start date. Trials have steadily increased over time and already have 10 started or planned for 2013.  (As an aside, Moe runs a thoughtful on LinkedIn for those interested in the clinical space: Breakthrough Solutions in Clinical Trials and Healthcare.)

Gilead Hepatitis C Map

Each week the editors of karmadata choose a Datacard created by one of our members, to recognize their creativity and contributions to the world’s open knowledge base.  This week’s Datacard visualizes clinical trial data for a popular biotech company (Gilead) for one of their development programs (Hepatitis C).  We copied this card (using its filters) and stamped out ~10 other Datacards, learning about Gilead’s drugs, clinical investigators and more in the Hepatitis C arena.  Great work!